Verve Therapeutics, Inc. Stock Price, News & Analysis

Verve Therapeutics has announced a collaboration with Vertex Pharmaceuticals, securing a $60 million upfront payment, which includes a $35 million equity investment. The partnership aims to develop an in vivo gene editing program targeting a specific liver disease over four years. Vertex will finance the research, while retaining rights to future development and commercialization. Verve could also earn up to $406 million in milestone payments and royalties on potential net sales. This collaboration marks a pivotal step in Verve's ongoing efforts to innovate gene editing therapies for cardiovascular diseases.

Verve Therapeutics announces the start of the Phase 1b clinical trial, heart-1, for its investigational gene editing medicine, VERVE-101, aimed at treating patients with heterozygous familial hypercholesterolemia (HeFH). The first patient has been dosed, marking a significant milestone in its development. VERVE-101 seeks to permanently deactivate the PCSK9 gene in the liver to reduce low-density lipoprotein cholesterol (LDL-C) levels. The trial plans to enroll around 40 participants, with interim data expected in 2023.

Verve Therapeutics has appointed Alexander G. “Bo” Cumbo, former CEO of AavantiBio, to its board of directors. Cumbo, who has over 28 years of experience in the pharmaceutical industry, brings a wealth of expertise in drug development and commercial execution. His appointment comes as Verve advances its regulatory strategy for VERVE-101 and its second program targeting ANGPTL3. The company aims to transform cardiovascular disease treatment from chronic management to single-course therapies, with VERVE-101 targeting familial hypercholesterolemia.

Verve Therapeutics will showcase its innovative approach to treating cardiovascular disease at the 2022 Jefferies Healthcare Conference. Co-founder and CEO Sekar Kathiresan will speak on June 8, 2022, at 1:00 p.m. ET in NYC. The company focuses on single-course gene editing medicines, specifically targeting PCSK9 and ANGPTL3 genes to lower LDL cholesterol levels. Verve’s lead candidate, VERVE-101, aims to reduce cardiovascular risk by permanently turning off the PCSK9 gene in the liver. A live webcast will be available on their investor website and archived for 60 days.

Verve Therapeutics has announced its strategic advancements for VERVE-101, aiming to treat heterozygous familial hypercholesterolemia (HeFH). The company has received clinical trial application clearance in New Zealand, with plans for a Phase 1 trial to start mid-2022 and initial data expected in 2023. Additionally, they are preparing regulatory submissions in the UK and US by late 2022. As of March 31, 2022, Verve holds $323.3 million in cash, providing a cash runway through 2024.

Verve Therapeutics announced significant results from its VERVE-101 program targeting heterozygous familial hypercholesterolemia (HeFH). The preclinical data revealed a mean 68% reduction in plasma LDL-C in non-human primates (NHPs) after a single intravenous infusion, with results sustained for up to one year. The administration was well-tolerated, and the GalNAc-Lipid Nanoparticle technology showed improved delivery potency, achieving a 98% reduction in blood ANGPTL3 after 15 days. Verve aims for global regulatory submissions this year to advance VERVE-101 into clinical trials.

Verve Therapeutics has announced that its CEO, Sekar Kathiresan, will participate in two significant investor conferences in May 2022. The first is the BofA Securities 2022 Healthcare Conference on May 11 at 2:40 p.m. PT in Las Vegas, followed by a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 p.m. ET in NYC. Live webcasts of both events will be accessible on the company’s website and archived for 60 days. Verve focuses on gene editing medicines to treat cardiovascular disease, with its lead product candidate, VERVE-101, targeting the PCSK9 gene to lower LDL-C levels.

Verve Therapeutics announced promising results from an off-target assessment of its lead candidate, VERVE-101, intended for treating cardiovascular disease. Whole genome sequencing showed minimal to no off-target editing in liver cells, supporting a favorable tolerability profile. VERVE-101 targets the PCSK9 gene to reduce LDL cholesterol. Verve aims to initiate clinical trials for heterozygous familial hypercholesterolemia in 2022. The findings will be presented at the Precision Genome Engineering Keystone Symposia on April 29, 2022.

Verve Therapeutics announces updated preclinical data on its base editing therapies targeting ANGPTL3 and PCSK9 genes for treating atherosclerotic cardiovascular disease (ASCVD). Data demonstrated durable and well-tolerated gene editing in non-human primates, with significant reductions in blood ANGPTL3 and PCSK9 proteins. The findings support the potential of these therapies to offer long-term LDL-C lowering solutions, particularly for patients with unmet needs. The data is being presented at the American College of Cardiology 71st Annual Scientific Session on April 4, 2022.